Literature DB >> 10478648

Kinetic analysis of [11C]McN5652: a serotonin transporter radioligand.

Z Szabo1, U Scheffel, W B Mathews, H T Ravert, K Szabo, M Kraut, S Palmon, G A Ricaurte, R F Dannals.   

Abstract

The impulse response function of a radioligand is the most fundamental way to describe its pharmacokinetics and to assess its tissue uptake and retention pattern. This study investigates the impulse response function of [11C](+)McN5652, a radioligand used for positron emission tomography (PET) imaging of the serotonin transporter (SERT) in the brain. Dynamic PET studies were performed in eight healthy volunteers injected with [11C](+)McN5652 and subsequently with its pharmacologically inactive enantiomer [11C](-)McN5652. The impulse response function was calculated by deconvolution analysis of regional time-activity curves, and its peak value (f(max)), its retention value at 75 minutes (fT), and its normalized retention (f(rel) = fT/f(max)) were obtained. Alternatively, compartmental models were applied to calculate the apparent total distribution volume (DV(T)) and its specific binding component (DV(S)). Both the noncompartmental (fT,f(rel)) and the compartmental parameters (DV) were investigated with and without correction for nonspecific binding by simple subtraction of the corresponding value obtained with [11C](-)McN5652. The impulse response function obtained by deconvolution analysis demonstrated high tracer extraction followed by a slow decline in the form of a monoexponential function. Statistical analysis revealed that the best compartmental model in terms of analysis of variance F and condition number of the parameter variance-covariance matrix was the one that was based on a single tissue compartment with parameters k1 and k2 and that also included the parameter of regional cerebral blood volume (BV). The parameter f(rel) demonstrated low between-subject variance (coefficient of variation [CV] = 19%), a midbrain to cerebellum ratio of 1.85, and high correlation with the known density of SERT (r = 0.787 where r is the coefficient of linear correlation between the parameter and the known density of SERT). After correction for nonspecific binding, f(rel) demonstrated further improvement in correlation (r = 0.814) and midbrain to cerebellum ratio (3.09). The variance of the distribution volumes was acceptable when the logarithmic transform lnDV was used instead of DV (17% for the three-parameter model), but correlation of this compartmental parameter was slightly less (r = 0.652 for the three-parameter model) than the correlation of the noncompartmental f(rel) with the known density of SERT, and the midbrain to cerebellum ratio was only 1.5 (uncorrected) and 1.8 (corrected). At the expense of increasing variance, the correlation was increased after correction for nonspecific binding using the inactive enantiomer (r = 0.694; CV = 22%). These results indicate that the kinetics of [11C](+)McN5652 can best be described by a one-tissue compartment model with three parameters (k1, k2, and BV), and that both the noncompartmental parameter f(rel) and the compartmental distribution volumes have the potential for quantitative estimation of the density of SERT. Further validation of the radioligand in experimental and clinical situations is warranted.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10478648      PMCID: PMC2034412          DOI: 10.1097/00004647-199909000-00004

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  32 in total

1.  McN-5652: a highly potent inhibitor of serotonin uptake.

Authors:  R P Shank; J L Vaught; K A Pelley; P E Setler; D F McComsey; B E Maryanoff
Journal:  J Pharmacol Exp Ther       Date:  1988-12       Impact factor: 4.030

2.  Effects of statistical noise and digital filtering on the parameters calculated from the impulse response function.

Authors:  Z Szabó; L Nyitrai; C Sondhaus
Journal:  Eur J Nucl Med       Date:  1987

Review 3.  Model identification and estimation of organ-function parameters using radioactive tracers and the impulse-response function.

Authors:  Z Szabó; H Vosberg; C A Sondhaus; L E Feinendegen
Journal:  Eur J Nucl Med       Date:  1985

4.  Regional and subcellular localization in human brain of [3H]paroxetine binding, a marker of serotonin uptake sites.

Authors:  M Laruelle; M A Vanisberg; J M Maloteaux
Journal:  Biol Psychiatry       Date:  1988-07       Impact factor: 13.382

5.  A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography.

Authors:  M A Mintun; M E Raichle; M R Kilbourn; G F Wooten; M J Welch
Journal:  Ann Neurol       Date:  1984-03       Impact factor: 10.422

6.  Pyrroloisoquinoline antidepressants. Potent, enantioselective inhibition of tetrabenazine-induced ptosis and neuronal uptake of norepinephrine, dopamine, and serotonin.

Authors:  B E Maryanoff; D F McComsey; M J Castanzo; P E Setler; J F Gardocki; R P Shank; C R Schneider
Journal:  J Med Chem       Date:  1984-08       Impact factor: 7.446

7.  Multiexponential, multicompartmental, and noncompartmental modeling. II. Data analysis and statistical considerations.

Authors:  E M Landaw; J J DiStefano
Journal:  Am J Physiol       Date:  1984-05

8.  Multiple regression for physiological data analysis: the problem of multicollinearity.

Authors:  B K Slinker; S A Glantz
Journal:  Am J Physiol       Date:  1985-07

9.  Serotoninergic terminal transporters are differentially affected in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study with [3H]citalopram.

Authors:  G Chinaglia; B Landwehrmeyer; A Probst; J M Palacios
Journal:  Neuroscience       Date:  1993-06       Impact factor: 3.590

10.  A PET radiotracer for studying serotonin uptake sites: carbon-11-McN-5652Z.

Authors:  M Suehiro; U Scheffel; R F Dannals; H T Ravert; G A Ricaurte; H N Wagner
Journal:  J Nucl Med       Date:  1993-01       Impact factor: 10.057

View more
  9 in total

1.  Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance.

Authors:  Una D McCann; Zsolt Szabo; Melin Vranesic; Michael Palermo; William B Mathews; Hayden T Ravert; Robert F Dannals; George A Ricaurte
Journal:  Psychopharmacology (Berl)       Date:  2008-07-27       Impact factor: 4.530

Review 2.  Development of (18)F-labeled radiotracers for neuroreceptor imaging with positron emission tomography.

Authors:  Peter Brust; Jörg van den Hoff; Jörg Steinbach
Journal:  Neurosci Bull       Date:  2014-08-29       Impact factor: 5.203

3.  Reversibility of ecstasy-induced reduction in serotonin transporter availability in polydrug ecstasy users.

Authors:  Ralph Buchert; Rainer Thomasius; Kay Petersen; Florian Wilke; Jost Obrocki; Bruno Nebeling; Lutz Wartberg; Pavlina Zapletalova; Malte Clausen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-08-17       Impact factor: 9.236

4.  Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB.

Authors:  Una D McCann; Zsolt Szabo; Esen Seckin; Peter Rosenblatt; William B Mathews; Hayden T Ravert; Robert F Dannals; George A Ricaurte
Journal:  Neuropsychopharmacology       Date:  2005-09       Impact factor: 7.853

5.  Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions.

Authors:  Zsolt Szabo; Una D McCann; Alan A Wilson; Ursula Scheffel; Taofeek Owonikoko; William B Mathews; Hayden T Ravert; John Hilton; Robert F Dannals; George A Ricaurte
Journal:  J Nucl Med       Date:  2002-05       Impact factor: 10.057

6.  Synthesis, radiolabeling and baboon SPECT imaging of 2beta-carbomethoxy-3beta-(3'-[(123)I]iodophenyl)tropane ([(123)I]YP256) as a serotonin transporter radiotracer.

Authors:  Frederic Bois; Ronald M Baldwin; Louis Amici; Mohammed S Al-Tikriti; Nora Kula; Ross Baldessarini; Robert B Innis; Julie K Staley; Gilles D Tamagnan
Journal:  Nucl Med Biol       Date:  2008-01       Impact factor: 2.408

7.  2-(2'-((Dimethylamino)methyl)-4'-(3-[(18)F]fluoropropoxy)-phenylthio)benzenamine for positron emission tomography imaging of serotonin transporters.

Authors:  Julie L Wang; Ajit K Parhi; Shunichi Oya; Brian Lieberman; Mei-Ping Kung; Hank F Kung
Journal:  Nucl Med Biol       Date:  2008-05       Impact factor: 2.408

8.  Compartmental modeling of 11C-HOMADAM binding to the serotonin transporter in the healthy human brain.

Authors:  Jonathon A Nye; John R Votaw; Nachwa Jarkas; David Purselle; Vernon Camp; James D Bremner; Clinton D Kilts; Charles B Nemeroff; Mark M Goodman
Journal:  J Nucl Med       Date:  2008-12       Impact factor: 10.057

9.  Quantitative positron emission tomography studies of the serotonin transporter in humans previously treated with the appetite suppressants fenfluramine or dexfenfluramine.

Authors:  Una D McCann; Zsolt Szabo; Melin Vranesic; Esen Seckin; Gary Wand; Anna Duval; Robert F Dannals; George A Ricaurte
Journal:  Mol Imaging Biol       Date:  2007 May-Jun       Impact factor: 3.484

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.